Noninvasive PD-L1 Imaging with 68Ga-WL12 PETCT to Detect Tumor Activity in Gastrointestinal Cancer Patients

What this Trial Is About

Researchers are studying a new, noninvasive imaging method called 68Ga-WL12 PETCT to detect PD-L1 expression in tumors of patients with gastrointestinal cancers. The goal is to identify which patients might benefit from anti-PD-1L1 treatments. This study is an interventional trial led by Peking University Cancer Hospital & Institute, focusing on solid tumors of the gastrointestinal tract. Participants in this single-arm study will all receive the 68Ga-WL12 PETCT scan, which uses a molecular imaging tracer WL12 labeled with Ga-68 to visualize PD-L1 expression in tumor lesions. This imaging technique is designed to help understand tumor behavior without invasive procedures. During the study, patients will undergo PETCT scans to measure the standardized uptake value SUV of the tracer in their tumors over a two-year period. Researchers will monitor and evaluate these imaging results to assess PD-L1 expression. Participants must meet certain health and tumor criteria and will be assessed for safety and eligibility throughout the study duration.

PD-L1 Targeting Molecular Imaging of Solid Tumors